{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:43:37Z","timestamp":1792813417707,"version":"4.5.0"},"reference-count":40,"publisher":"Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Psoriasis may affect patients\u2019 sleep. In order to examine this relationship, this study evaluated non-anxious and non-depressive patients with moderate to severe psoriasis before and after 6 months of systemic treatment. A prospective case-control study with 46 consecutive patients (mean age 51.1\u2009\u00b1\u200912.8 years, 18 women) and 24 age-, sex- and body mass index-matched controls (mean age 46.5\u2009\u00b1\u200915.4 years, 12 women) was conducted to assess sleep using both sleep questionnaires and actigraphy. Of psoriatic patients, 91.3% were poor sleepers, and 65.2% of the psoriatic patients presented insomnia symptoms, compared with 54.2% and 33.3% of the control group (p\u2009&lt;\u20090.001, p\u2009=\u20090.02, respectively). Actigraphy showed that Total Sleep Time was shorter in patients, while 82.6% of the psoriatic patients had poor Sleep Efficiency, compared with controls (p\u2009=\u20090.004, p\u2009=\u20090.03, respectively). Patients\u2019 quality of life was associated with sleep disturbance (p\u2009&lt;\u20090.001), and pruritus was negatively correlated with sleep duration (p\u2009&lt;\u20090.001). After 6 months of treatment, patients\u2019 sleep pattern, according to actigraphy, had not changed significantly; however, they had insomnia for no longer than the control group (p\u2009=\u20090.65), whereas the above-mentioned correlations were non-significant after treatment. Psoriatic insomnia was improved after 6 months of systemic treatment. Actigraphy may be used as an objective tool to evaluate sleep in these patients.\u00a0<\/jats:p>","DOI":"10.2340\/actadv.v103.4507","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T15:04:46Z","timestamp":1676387086000},"page":"adv00864","source":"Crossref","is-referenced-by-count":17,"title":["Psoriatic Insomnia: A Subjective and Objective Sleep Evaluation"],"prefix":"10.2340","volume":"103","author":[{"given":"Katerina","family":"Vlami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kleoniki","family":"Pantelidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Dalamaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fani","family":"Karagianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Theodoropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon","family":"Papiris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Papadavid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"25686","doi-asserted-by":"crossref","unstructured":"Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263\u2013271.","DOI":"10.1016\/S0140-6736(07)61128-3"},{"key":"25687","doi-asserted-by":"crossref","unstructured":"Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths C.E.M, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1\u201310.","DOI":"10.1007\/s00403-010-1080-1"},{"key":"25688","doi-asserted-by":"crossref","unstructured":"Smith MP, Ly K, Thibodeaux Q, Weerasinghe T, Beck K, Shankle L, et al. Factors influencing sleep difficulty and sleep quantity in the Citizen Pscientist Psoriatic Cohort. Dermatol Ther 2019; 9: 511\u2013523.","DOI":"10.1007\/s13555-019-0306-1"},{"key":"25689","doi-asserted-by":"crossref","unstructured":"Thorburn PT, Riha RL. Skin disorders and sleep in adults: where is the evidence? Sleep Med Rev 2010; 14: 351\u2013358.","DOI":"10.1016\/j.smrv.2009.12.001"},{"key":"25690","doi-asserted-by":"crossref","unstructured":"Irwin, MR. Why sleep is important for health: a psychoneuroimmunology perspective. Annu Rev Psychol 2015; 3: 143\u2013172.","DOI":"10.1146\/annurev-psych-010213-115205"},{"key":"25691","doi-asserted-by":"crossref","unstructured":"Irwin MR, Olmstead R, Carroll JE. Sleep disturbance, sleep duration, and inflammation: a systematic review and meta-analysis of cohort studies and experimental sleep deprivation. Biol Psychiatry 2016; 80: 40\u201352.","DOI":"10.1016\/j.biopsych.2015.05.014"},{"key":"25692","doi-asserted-by":"crossref","unstructured":"Dalamaga M, Papadavid E, Vlami K. Unmasking the Janus face of the association between psoriasis, metabolic syndrome and obstructive sleep apnea. Sleep Breath 2013; 17: 449\u2013450.","DOI":"10.1007\/s11325-012-0749-4"},{"key":"25693","unstructured":"Papadavid E, Vlami K, Dalamaga M, Giatrakou S, Theodoropoulos K, Gyftopoulos S, et al. Sleep apnea as a comorbidity in obese psoriasis patients: a cross-sectional study. Do psoriasis characteristics and metabolic parameters play a role? J Eur Acad Dermatol Venereol 2013; 27: 820\u2013826."},{"key":"25694","doi-asserted-by":"crossref","unstructured":"Papadavid E, Dalamaga M, Vlami K, Koumaki D, Gyftopoulos S, Christodoulatos GS, et al. Psoriasis is associated with risk of obstructive sleep apnea independently from metabolic parameters and other comorbidities: a large hospital-based case control study. Sleep Breath 2017; 21: 949\u2013958.","DOI":"10.1007\/s11325-017-1507-4"},{"key":"25695","doi-asserted-by":"crossref","unstructured":"Henry AL, Kyle SD, Chisholm A, Griffiths CEM, Bundy C. A cross sectional survey of the nature and correlates of sleep disturbance in people with psoriasis. Br J Dermatol 2017; 177: 1052\u20131059.","DOI":"10.1111\/bjd.15469"},{"key":"25696","doi-asserted-by":"crossref","unstructured":"Jensen P, Zachariae C, Skov L, Zachariae R. Sleep disturbance in psoriasis \u2013 a case-controlled study. Br J Dermatol 2018; 179: 1376\u20131384.","DOI":"10.1111\/bjd.16702"},{"key":"25697","doi-asserted-by":"crossref","unstructured":"Henry AL, Chisholm A, Carter LA, Bundy C, Griffiths CEM, Kyle SD. The relationship between sleep disturbance, symptoms and daytime functioning in psoriasis: a prospective study integrating actigraphy and experience sampling methodology. Sleep Medicine 2020; 72: 144\u2013149.","DOI":"10.1016\/j.sleep.2020.03.013"},{"key":"25698","doi-asserted-by":"crossref","unstructured":"Buysse DJ, Reynolds 3rd CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1988; 28: 193\u2013213.","DOI":"10.1016\/0165-1781(89)90047-4"},{"key":"25699","unstructured":"Perantoni E, Steiropoulos P, Siopi D, Amfilochiou A, Michailidis V, Christoforatou K, et al. Validation of the Greek version of Pittsburg sleep quality questionnaire in a sleep lab population. Eur Respir J 2012; 40: P903."},{"key":"25700","doi-asserted-by":"crossref","unstructured":"Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res 2000; 48: 555\u2013560.","DOI":"10.1016\/S0022-3999(00)00095-7"},{"key":"25701","doi-asserted-by":"crossref","unstructured":"Soldatos CR, Dikeos DG, Paparrigopoulos TJ. The diagnostic validity of the Athens Insomnia Scale. J Psychos Res 2003; 55: 263\u2013267.","DOI":"10.1016\/S0022-3999(02)00604-9"},{"key":"25702","unstructured":"Johns MW. Daytime sleepiness, snoring and obstructive sleep apnea. The Epworth Sleepiness Scale. Chest 1993; 103: 30\u201336."},{"key":"25703","doi-asserted-by":"crossref","unstructured":"Tsara V, Serasli E, Amfilochiou A, Constantinidis T, Christaki P. Greek version of the Epworth Sleepiness Scale. Sleep Breath 2004; 8: 91\u201395.","DOI":"10.1055\/s-2004-829632"},{"key":"25704","doi-asserted-by":"crossref","unstructured":"Marino M, Yi Li, Rueschman NM, Wilkelman JW, Ellenbogen JM, Solet JM, et al. Measuring sleep: accuracy, sensitivity, and specificity of wrist actigraphy compared to polysomnography. Sleep 2013; 36: 1747\u20131755.","DOI":"10.5665\/sleep.3142"},{"key":"25705","doi-asserted-by":"crossref","unstructured":"Zachariae R, Zachariae COC, Lei U, Pedersen AF. Affective and sensory dimensions of pruritus severity: associations with psychological symptoms and quality of life in psoriasis patients. Acta Derm Venereol 2008; 88: 121\u2013127.","DOI":"10.2340\/00015555-0371"},{"key":"25706","doi-asserted-by":"crossref","unstructured":"Yosipovitch G, Goon A, Wee J, Chan YH, Goh CL. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 2000; 143: 969\u2013973.","DOI":"10.1046\/j.1365-2133.2000.03829.x"},{"key":"25707","doi-asserted-by":"crossref","unstructured":"Hirotsu C, Rydlewski M, Ara\u00fajo MS, Tufik S, Andersen ML. Sleep loss and cytokines levels in an experimental model of psoriasis. PLoS One 2012; 7: e5118.","DOI":"10.1371\/journal.pone.0051183"},{"key":"25708","unstructured":"Moynihan J, Rieder E, Tausk F. Psychoneuroimmunology: the example of psoriasis. J Ital Dermatol Venereol 2010; 145: 221\u2013228."},{"key":"25709","doi-asserted-by":"crossref","unstructured":"Covassin N, Singh P. Sleep duration and cardiovascular disease risk: epidemiologic and experimental evidence. Sleep Med Clin 2016; 11: 81\u201389.","DOI":"10.1016\/j.jsmc.2015.10.007"},{"key":"25710","doi-asserted-by":"crossref","unstructured":"Seow LSE, Tan XW, Chong SA, Vaingankar JA, Abdim E, Shafie S, et al. Independent and combined associations of sleep duration and sleep quality with common physical and mental disorders: results from a multi-ethnic population-based study. PLoS One 2020; 15: 1\u201317.","DOI":"10.1371\/journal.pone.0235816"},{"key":"25711","doi-asserted-by":"crossref","unstructured":"Shutty BG, West C, Huang KE, Landis E, Dabade T, Browder B, et al. Sleep disturbances in psoriasis. Dermatol Online J 2013; 19: 1.","DOI":"10.5070\/D30073R324"},{"key":"25712","doi-asserted-by":"crossref","unstructured":"Riemann D, Voderholzer U. Primary insomnia: a risk factor to develop depression? J Affect Disord 2003; 76: 255\u2013259.","DOI":"10.1016\/S0165-0327(02)00072-1"},{"key":"25713","doi-asserted-by":"crossref","unstructured":"Dag Neckelmann. Chronic insomnia as a risk factor for developing anxiety and depression. Sleep 2007; 30: 873\u2013880.","DOI":"10.1093\/sleep\/30.7.873"},{"key":"25714","doi-asserted-by":"crossref","unstructured":"Fernandez-Mendoza J, Baker JH, Vgontzas AN, Gaines J, Liao D, Bixler EO. Insomnia symptoms with objective short sleep duration are associated with systemic inflammation in adolescents. Brain Behav Immun 2017; 61: 110\u2013116.","DOI":"10.1016\/j.bbi.2016.12.026"},{"key":"25715","unstructured":"Berk M, Williams LJ, Jacka FN, O\u2019Neil A, Pasco J.A, Moylan S, et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med 2013; 11: 200."},{"key":"25716","doi-asserted-by":"crossref","unstructured":"Irwin MR, Piber D. Insomnia and inflammation: a two hit model of depression risk and prevention. World Psychiatry 2018; 17: 359\u2013361.","DOI":"10.1002\/wps.20556"},{"key":"25717","doi-asserted-by":"crossref","unstructured":"Buysse DJ. Insomnia. JAMA 2013; 309: 706\u2013716.","DOI":"10.1001\/jama.2013.193"},{"key":"25718","doi-asserted-by":"crossref","unstructured":"Singh S, Taylor C, Kornmehl H, Armstrong A.W. Psoriasis and suicidality: a systematic review and meta-analysis. J Am Acad Dermatol 2017; 77: 425\u2013440.","DOI":"10.1016\/j.jaad.2017.05.019"},{"key":"25719","doi-asserted-by":"crossref","unstructured":"Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther 2022; 16: 1\u20133.","DOI":"10.1080\/14712598.2022.2113872"},{"key":"25720","doi-asserted-by":"crossref","unstructured":"Wu C-Y, Chang Y-T, Juan C-K, Shen J-L, Lin Y-P, Shieh J-J, et al. Depression and insomnia in patients with psoriasis and psoriatic arthritis taking tumor necrosis factor antagonists. Medicine 2016; 95: e3816.","DOI":"10.1097\/MD.0000000000003816"},{"key":"25721","doi-asserted-by":"crossref","unstructured":"Zamarr\u00f3n C, Maceiras F, Mera A, Gomez-Reino JJ. Effect of the first infliximab infusion on sleep and alertness in patients with active rheumatoid arthritis. Ann Rheum Dis 2004; 63: 88\u201390.","DOI":"10.1136\/ard.2003.007831"},{"key":"25722","doi-asserted-by":"crossref","unstructured":"Strober BE, Sobell JM, Duffin KC, Bao Y, Guerin A, Yang H, et al. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial. Br J Dermatol 2012; 167: 1374\u20131381.","DOI":"10.1111\/bjd.12000"},{"key":"25723","doi-asserted-by":"crossref","unstructured":"Thaci D, Galimberti R, Guerra MA, Rosenbach T, Robertson D, Pedersen R, et al. Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial. J Eur Acad Dermatol Venereol 2014; 28: 900\u2013906.","DOI":"10.1111\/jdv.12207"},{"key":"25724","doi-asserted-by":"crossref","unstructured":"Radi G, Campanati A, Diotallevi F, Rizzetto G, Martina E, Bobyr I, et al. Long-term efficacy and safety of apremilast in the treatment of plaques psoriasis: a real-world, single-center experience. Dermatol Ther 2021; 34: e15179.","DOI":"10.1111\/dth.15179"},{"key":"25725","doi-asserted-by":"crossref","unstructured":"Kapniari E, Dalamaga M, Papadavid E. Comorbidities burden and previous exposure to biological agents may predict drug survival of apremilast for psoriasis in a real-world setting. Dermatol Ther 2020; 33: e14168.","DOI":"10.1111\/dth.14168"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/4507\/13190","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/4507\/13190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T07:47:05Z","timestamp":1679730425000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/4507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":40,"URL":"https:\/\/doi.org\/10.2340\/actadv.v103.4507","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,14]]}}}